UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases
UCB (EBR: UCB) announced on May 3, 2026, a definitive agreement to acquire Candid Therapeutics...
AstraZeneca’s Truqap Receives Positive ODAC Recommendation for PTEN-Deficient mHSPC Based on CAPItello-281 Trial Data
AstraZeneca plc (NYSE: AZN) announced that the US Food and Drug Administration’s (FDA) Oncologic Drugs...
SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease
SiranBio, a Suzhou-based siRNA drug developer, announced a strategic licensing agreement with GlaxoSmithKline plc (GSK;...
Avistone Biotechnology’s Andatinib Receives China Conditional Approval for EGFR Ex20ins NSCLC
Beijing Avistone Biotechnology Co., Ltd. announced that its self-developed EGFR exon 20 insertion (ex20ins) inhibitor,...
GE Healthcare Reports 7.4% Q1 Revenue Growth to $5.1B Driven by Imaging and Pharmaceutical Diagnostics Strength
GE Healthcare Technologies Inc. (NASDAQ: GEHC) reported first-quarter 2026 financial results with revenues of USD...
GE Healthcare Restructures Imaging Business with $14.6B AIS Segment and New Executive Leadership
GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced a major organizational restructuring aimed at driving stronger...
AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength
AstraZeneca PLC (NYSE: AZN) reported first-quarter 2026 financial results with total revenue of USD 15.288...
BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that the U.S....
Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength
Innovent Biologics, Inc. (HKG: 1801) reported Q1 2026 product sales exceeding RMB 3.8 billion (USD...
Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer
Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that its investigational antibody-drug conjugate (ADC) HS-20093...
Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam
Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) and Emalex Biosciences announced a definitive acquisition agreement under...
AbbVie Reports 12.4% Revenue Growth in Q1 2026 Driven by Immunology and Neuroscience Strength
AbbVie Inc. (NYSE: ABBV) reported first quarter 2026 financial results with worldwide net revenues of...
3SBio Reports 94% Revenue Surge to $2.58B in 2025 Driven by $6B Pfizer PD-1/VEGF Bispecific Antibody Deal
3SBio Inc. (HKG: 1530) reported 2025 financial results with revenues soaring 94.3% year-over-year (YOY) to...
Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline
Eccogene Inc., a Sino-U.S. biotechnology company founded in 2018, has filed its prospectus for an...
Lianhuan Pharmaceutical’s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial
Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced that its Phase III clinical study for...
Allist Pharmaceuticals Secures NMPA Approval for Pivotal Trial of Furmonertinib Against Standard EGFR TKIs in Rare NSCLC Mutations
Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China’s National Medical Products Administration (NMPA) has...
Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate
Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that China’s regulatory authorities have granted Breakthrough Therapy...
Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported first quarter 2026 financial results with revenues increasing 19%...
Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026
Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has...
Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has assumed exclusive licensing rights from...